A video method for the evaluation of antidepressant clinical and behavioural actions

Martin M. Katz, John P. Houston, Stephen Brannan, Janet Tekell, Nancy Berman, Charles L. Bowden, Alan Frazer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Measuring efficacy and behavioural actions of new antidepressants (ADs) is greatly enhanced by having videotaped records of assessment interviews. This study describes a revised version of the Video Interview Behaviour Evaluation Scales (VIBES), shortened to make it more applicable to clinical trials. The method focuses on physically expressive, motor and social behavioural aspects of the depressive disorder. The Brief version permits juxtaposing of baseline and outcome interviews during the same viewing session thereby reducing the role of memory in the rater's observations. The method provides measures of behavioural components and four new severity dimensions, Social withdrawal-motor retardation, Anxiety-agitation, Hostility, Depressive mood-cognitive impairment. Viewing a patient's series of baseline, during treatment, and outcome interviews can be conducted in about 1 h. This study compared the VIBES with the Hamilton Depression Rating Scale (HAMD) in (1) assessing the efficacy of the selectively targeted ADs, desipramine and paroxetine, and placebo in depressed in-patients and (2) determining onset and nature of the drugs' early behavioural actions. The findings showed (1) components of the method to be reliable; (2) the VIBES to be more sensitive than the HAMD in measuring efficacy; (3) the methods to be equally sensitive in detecting early clinical actions of the two drugs; (4) the VIBES more informative in identifying discrete behavioural aspects of the disorder that are impacted by the drugs; and (5) that in differentiating the drugs' behavioural actions, desipramine was indicated to initially 'stimulate', i.e. effect motor activity and depressed mood, and paroxetine to reduce global severity and anxiety. The study shows the VIBES to be capable of uncovering behavioural mechanisms underlying AD's capacity to resolve depressive disorder.

Original languageEnglish (US)
Pages (from-to)327-336
Number of pages10
JournalInternational Journal of Neuropsychopharmacology
Volume9
Issue number3
DOIs
StatePublished - Jun 2006

Fingerprint

Antidepressive Agents
Interviews
Paroxetine
Desipramine
Depressive Disorder
Pharmaceutical Preparations
Anxiety
Hostility
Motor Activity
Placebos
Clinical Trials
Depression

Keywords

  • Antidepressants
  • Behavioural actions
  • Clinical trials
  • Onset
  • Video method

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A video method for the evaluation of antidepressant clinical and behavioural actions. / Katz, Martin M.; Houston, John P.; Brannan, Stephen; Tekell, Janet; Berman, Nancy; Bowden, Charles L.; Frazer, Alan.

In: International Journal of Neuropsychopharmacology, Vol. 9, No. 3, 06.2006, p. 327-336.

Research output: Contribution to journalArticle

Katz, Martin M. ; Houston, John P. ; Brannan, Stephen ; Tekell, Janet ; Berman, Nancy ; Bowden, Charles L. ; Frazer, Alan. / A video method for the evaluation of antidepressant clinical and behavioural actions. In: International Journal of Neuropsychopharmacology. 2006 ; Vol. 9, No. 3. pp. 327-336.
@article{19b5e39c97a04837ab207787fec4ce8a,
title = "A video method for the evaluation of antidepressant clinical and behavioural actions",
abstract = "Measuring efficacy and behavioural actions of new antidepressants (ADs) is greatly enhanced by having videotaped records of assessment interviews. This study describes a revised version of the Video Interview Behaviour Evaluation Scales (VIBES), shortened to make it more applicable to clinical trials. The method focuses on physically expressive, motor and social behavioural aspects of the depressive disorder. The Brief version permits juxtaposing of baseline and outcome interviews during the same viewing session thereby reducing the role of memory in the rater's observations. The method provides measures of behavioural components and four new severity dimensions, Social withdrawal-motor retardation, Anxiety-agitation, Hostility, Depressive mood-cognitive impairment. Viewing a patient's series of baseline, during treatment, and outcome interviews can be conducted in about 1 h. This study compared the VIBES with the Hamilton Depression Rating Scale (HAMD) in (1) assessing the efficacy of the selectively targeted ADs, desipramine and paroxetine, and placebo in depressed in-patients and (2) determining onset and nature of the drugs' early behavioural actions. The findings showed (1) components of the method to be reliable; (2) the VIBES to be more sensitive than the HAMD in measuring efficacy; (3) the methods to be equally sensitive in detecting early clinical actions of the two drugs; (4) the VIBES more informative in identifying discrete behavioural aspects of the disorder that are impacted by the drugs; and (5) that in differentiating the drugs' behavioural actions, desipramine was indicated to initially 'stimulate', i.e. effect motor activity and depressed mood, and paroxetine to reduce global severity and anxiety. The study shows the VIBES to be capable of uncovering behavioural mechanisms underlying AD's capacity to resolve depressive disorder.",
keywords = "Antidepressants, Behavioural actions, Clinical trials, Onset, Video method",
author = "Katz, {Martin M.} and Houston, {John P.} and Stephen Brannan and Janet Tekell and Nancy Berman and Bowden, {Charles L.} and Alan Frazer",
year = "2006",
month = "6",
doi = "10.1017/S1461145705005778",
language = "English (US)",
volume = "9",
pages = "327--336",
journal = "The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "3",

}

TY - JOUR

T1 - A video method for the evaluation of antidepressant clinical and behavioural actions

AU - Katz, Martin M.

AU - Houston, John P.

AU - Brannan, Stephen

AU - Tekell, Janet

AU - Berman, Nancy

AU - Bowden, Charles L.

AU - Frazer, Alan

PY - 2006/6

Y1 - 2006/6

N2 - Measuring efficacy and behavioural actions of new antidepressants (ADs) is greatly enhanced by having videotaped records of assessment interviews. This study describes a revised version of the Video Interview Behaviour Evaluation Scales (VIBES), shortened to make it more applicable to clinical trials. The method focuses on physically expressive, motor and social behavioural aspects of the depressive disorder. The Brief version permits juxtaposing of baseline and outcome interviews during the same viewing session thereby reducing the role of memory in the rater's observations. The method provides measures of behavioural components and four new severity dimensions, Social withdrawal-motor retardation, Anxiety-agitation, Hostility, Depressive mood-cognitive impairment. Viewing a patient's series of baseline, during treatment, and outcome interviews can be conducted in about 1 h. This study compared the VIBES with the Hamilton Depression Rating Scale (HAMD) in (1) assessing the efficacy of the selectively targeted ADs, desipramine and paroxetine, and placebo in depressed in-patients and (2) determining onset and nature of the drugs' early behavioural actions. The findings showed (1) components of the method to be reliable; (2) the VIBES to be more sensitive than the HAMD in measuring efficacy; (3) the methods to be equally sensitive in detecting early clinical actions of the two drugs; (4) the VIBES more informative in identifying discrete behavioural aspects of the disorder that are impacted by the drugs; and (5) that in differentiating the drugs' behavioural actions, desipramine was indicated to initially 'stimulate', i.e. effect motor activity and depressed mood, and paroxetine to reduce global severity and anxiety. The study shows the VIBES to be capable of uncovering behavioural mechanisms underlying AD's capacity to resolve depressive disorder.

AB - Measuring efficacy and behavioural actions of new antidepressants (ADs) is greatly enhanced by having videotaped records of assessment interviews. This study describes a revised version of the Video Interview Behaviour Evaluation Scales (VIBES), shortened to make it more applicable to clinical trials. The method focuses on physically expressive, motor and social behavioural aspects of the depressive disorder. The Brief version permits juxtaposing of baseline and outcome interviews during the same viewing session thereby reducing the role of memory in the rater's observations. The method provides measures of behavioural components and four new severity dimensions, Social withdrawal-motor retardation, Anxiety-agitation, Hostility, Depressive mood-cognitive impairment. Viewing a patient's series of baseline, during treatment, and outcome interviews can be conducted in about 1 h. This study compared the VIBES with the Hamilton Depression Rating Scale (HAMD) in (1) assessing the efficacy of the selectively targeted ADs, desipramine and paroxetine, and placebo in depressed in-patients and (2) determining onset and nature of the drugs' early behavioural actions. The findings showed (1) components of the method to be reliable; (2) the VIBES to be more sensitive than the HAMD in measuring efficacy; (3) the methods to be equally sensitive in detecting early clinical actions of the two drugs; (4) the VIBES more informative in identifying discrete behavioural aspects of the disorder that are impacted by the drugs; and (5) that in differentiating the drugs' behavioural actions, desipramine was indicated to initially 'stimulate', i.e. effect motor activity and depressed mood, and paroxetine to reduce global severity and anxiety. The study shows the VIBES to be capable of uncovering behavioural mechanisms underlying AD's capacity to resolve depressive disorder.

KW - Antidepressants

KW - Behavioural actions

KW - Clinical trials

KW - Onset

KW - Video method

UR - http://www.scopus.com/inward/record.url?scp=33646862132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646862132&partnerID=8YFLogxK

U2 - 10.1017/S1461145705005778

DO - 10.1017/S1461145705005778

M3 - Article

C2 - 16035957

AN - SCOPUS:33646862132

VL - 9

SP - 327

EP - 336

JO - The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)

JF - The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)

SN - 1461-1457

IS - 3

ER -